Trial Profile
A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs BMS-986258 (Primary) ; Nivolumab (Primary) ; Hyaluronidase
- Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Male breast cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 08 Apr 2024 Planned End Date changed from 28 Dec 2024 to 15 Apr 2025.
- 06 Sep 2023 Planned End Date changed from 20 Mar 2023 to 28 Dec 2024.
- 06 Sep 2023 Planned primary completion date changed from 20 Mar 2023 to 28 Dec 2024.